StockNews.com downgraded shares of ResMed (NYSE:RMD – Free Report) from a buy rating to a hold rating in a research report report published on Wednesday morning. A number of other equities research ...

A new study has found that people who spend time on their devices in bed are likely to suffer from sleep loss and insomnia.

Shares of ResMed Inc. RMD slid 3.83% to $205.17 Friday, on what proved to be an all-around dismal trading session for the ...

The home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea ...

A new Resmed-supported study showing sleep apnea patients on CPAP therapy live longer will further fuel a “once-in-a-generation opportunity” to increase awareness, says Carlos Nunez, ...

Once considered a secondary option to hospital-based treatment, industry experts say home respiratory care has now become the standard for managing chronic conditions.

RMD recently launched its home sleep apnea test, NightOwl, across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT), designed to offer healthcare providers a simplified, ...

Leading health technology, Resmed, has announced its home sleep apnea test, NightOwl, is now available across the United ...

ResMed Inc. closed 18.89% short of its 52-week high of $263.05, which the company reached on January 30th.

NightOwl, an FDA-cleared home sleep apnea test (HSAT) offers a simplified, accurate, efficient way to diagnose obstructive sleep apnea (OSA). It adds another offering to Resmed’s portfolio, which is ...

ResMed (NYSE:RMD) launched NightOwl™, a home sleep apnea test that enhances user convenience with a small fingertip sensor and cloud data evaluation. Despite the broader market reacting negatively to ...

Which is the better option for ASX investors, Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) or ResMed Inc. (ASX: RMD) ...